NCT07057271View on ClinicalTrials.gov

A Study of CJC-1134-PC Injection in Patients With Type 2 Diabetes With Inadequately Controlled Blood Glucose Level After Metformin Monotherapy or Metformin in Combination With Insulin Secretagogues

PHASE3CompletedINTERVENTIONAL
Enrollment

464

Participants

Timeline

Start Date

May 27, 2021

Primary Completion Date

February 21, 2023

Study Completion Date

February 21, 2023

Conditions
Type 2 Diabetes Mellitus - Poor Control
Interventions
DRUG

CJC-1134-PC Injection

Double-blind Treatment Period: 0.2ml (2mg) once weekly ×24 weeks (Week 1 to Week 24); Open-label Treatment Period: 0.2ml (2mg) once weekly ×28 weeks (Week 25 to Week 52)

DRUG

Placebo

Double-blind Treatment Period: 0.2ml (0mg) once weekly ×24 weeks (Week 1 to Week 24); Open-label Treatment Period: 0.2ml (2mg) once weekly ×28 weeks (Week 25 to Week 52)

Trial Locations (1)

100044

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.

INDUSTRY